News

Sonnet BioTherapeutics to Showcase Cancer Research at Major Event

Sonnet BioTherapeutics to Showcase Cancer Research at Major Event

Sonnet BioTherapeutics to Present at Prominent Cancer Research Conference

Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN), a pioneering clinical-stage biotechnology firm focused on developing innovative immunotherapeutic drugs, has exciting news to share. The company has had its abstract accepted for poster presentation at one of the most significant conferences in the oncology field, the 2025 American Association for Cancer Research (AACR) IO Conference. This event is scheduled from February 23-26, 2025, and will take place at the JW Marriott in Los Angeles.

Details of the Presentation

Attendees can look forward to a detailed exploration of Sonnet's research during Poster Session B. The abstract is titled “Combination immunotherapy with an albumin-binding interleukin-12 fusion protein that extends cytokine half-life, targets the tumor microenvironment, and enhances therapeutic efficacy.” This important presentation will be held on Tuesday, February 25, 2025, from 1:45-4:45 PM PT.

What is Sonnet BioTherapeutics?

Sonnet BioTherapeutics is known for its unique approach to fighting cancer through targeted biologic therapies. Their proprietary FHAB (Fully Human Albumin-Binding) technology allows them to develop drugs that specifically target tumors and lymphatic tissue while utilizing the body's own transport mechanisms. This targeted approach enhances the safety and efficacy of biologic drugs designed to modulate immune responses.

Innovative Drug Development

Central to their development pipeline is SON-1010, or IL-12-FHAB, which is being tested as a treatment for various advanced solid tumors, including specific sarcomas and platinum-resistant ovarian cancer (PROC). This program is currently in an ongoing Phase 1/2a clinical study, leveraging a collaboration with Roche. The study is notable for combining SON-1010 with atezolizumab, a well-known immune checkpoint inhibitor. The early data from these studies are highly promising and support the potential broadened application of immunotherapies.

Expanding Horizons with New Candidates

In addition to SON-1010, Sonnet is actively engaged in the development of SON-1210, another candidate designed for treating solid tumors. This candidate combines IL-12-FHAB with IL-15 and is being explored through a partnership with the Innovative Immuno-Oncology Consortium (IIOC). There are plans for an investigator-initiated and funded Phase 1/2a study targeting locally-advanced or metastatic pancreatic ductal adenocarcinoma (PDAC).

Sonnet’s Commitment to Neuropathy Research

Moreover, the company is advancing their SON-080 program, which focuses on the treatment of Chemotherapy-Induced Peripheral Neuropathy (CIPN) and Diabetic Peripheral Neuropathy (DPN). Encouraging results have emerged from the Phase 1b/2a clinical trial where SON-080 was well-tolerated, showing no signs of pro-inflammatory cytokine response. Recently, Sonnet entered into a licensing agreement with Alkem Laboratories, Inc., which will lead the development of SON-080 into a continuation into a Phase 2 study in DPN.

Why Attend the AACR Conference?

The AACR Climate Conference represents a wonderful opportunity for Sonnet to share its latest findings with a community of researchers and healthcare professionals dedicated to cancer research and treatment. By presenting at such a prestigious conference, the company also seeks to attract attention to its innovative therapies, gather insights from peers, and forge potential collaborations aimed at advancing cancer treatments.

Future Directions

As Sonnet BioTherapeutics continues to develop its innovative therapies, the company remains committed to enhancing the quality of life for cancer patients and addressing unmet medical needs. Their ongoing clinical trials and collaborations reflect an eagerness to advance the scientific understanding and therapeutic landscape in oncology.

Frequently Asked Questions

What is the significance of Sonnet's presentation at the AACR conference?

This presentation highlights Sonnet's contributions to cancer immunotherapy and allows for networking with other professionals in the field.

What technologies does Sonnet BioTherapeutics use?

Sonnet uses its FHAB technology to develop targeted biologic therapies specifically aimed at tumor and lymphatic tissues.

What are SON-1010 and SON-1210?

SON-1010 and SON-1210 are advanced immunotherapeutics currently in development for treating solid tumors and enhancing the efficacy of cancer treatments.

How is Sonnet involved in neuropathy treatment?

Sonnet's SON-080 program is designed to address chemotherapy-induced and diabetic peripheral neuropathy with promising clinical results.

Where can I learn more about Sonnet BioTherapeutics?

For further information, you can contact their investor relations team or visit their official website.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Smart Cooling Accessory: A Game Changer for AC Units?

Updated Category News Views 0

New Kid on the Block: The Smart Cooling Game They say the devil's in the details, and this one’s got all the right tweaks. Picture this — a compressor-based air conditioning system beefing up with a savvy accessory that promises to give your condenser coil some extra muscle. That's right, we've got ourselves a new contender in the cooling corner: THE CSC UNIT. It's...

Continue Reading
Nutex Health Scores Top Workplace Honor in 2026

Updated Category News Views 105

Nutex Health: Accolades and Aspirations Nutex Health just snagged something pretty noteworthy: They've been crowned a 2026 Houston Top Workplace by the Houston Chronicle. Now, before you start throwing confetti, let's chew on what this really means. It's no small potatoes, folks. We're talking employee respect and satisfaction measured by Energage’s surveys. It's proof...

Continue Reading
CHARMANT Eyewear Fuses Fashion and Functionality

Updated Category News Views 54

Eyewear ain’t just about seeing clearly anymore—it’s fashion with a capital ‘F’. The CHARMANT Japanese Made brand decided to foist this idea upon the world, putting their money where your eyeballs are, by injecting a dose of trendy glam into what they already do so well: comfort. Fusion of Style and Comfort Catch this: CHARMANT hit the global stage back in June...

Continue Reading
Human Development Fund's Bold Partnership for Growth

Updated Category News Views 54

An Unusual Alliance with Far-Reaching Implications Every once in a while, a nonprofit steps up with a move that makes even the toughest investors take notice. This isn't some Wall Street ticker talk, sure, but it’s worth turning your chair toward the table. The Human Development Fund (HDF) has penned a strategic deal with the Islamic Development Bank (IsDB), putting its...

Continue Reading
Millrose Faces Class Action Over Misleading Investors

Updated Category News Views 6

Millrose Properties Steps Into Legal Hot Water Ah, stocks and legal squabbles—a pairing as old as Wall Street itself. Now, folks, it seems Millrose Properties, Inc. has stepped right onto the chopping block with a lawsuit knocking on their door over claims they misled investors. The suits from the DJS Law Group aren't mince words: we're talking alleged violations of the...

Continue Reading
CureGene's Evategrel Aims for Breakthrough in Stroke Care

Updated Category News Views 217

Revolutionizing Stroke Care: Enter Evategrel When it comes to strokes, time is money—and I'm telling you, this ain't an area where you can afford to twiddle your thumbs. The faster you can get that blood flowing again, the better the chance you've got of walking away with less damage. That's where CureGene's new investigational drug, Evategrel, comes in. Why Evategrel...

Continue Reading
Xinjiang Women Embrace New Horizons in Tianshan Peaks

Updated Category News Views 89

Scaling New Heights in Xinjiang Up there on the Tianshan Mountains, looking past those towering cliffs, what catches the eye isn't just breathtaking views but rising opportunities. In the land of Xinjiang, far from the bustling metropolises, young women are finding platforms to not just exist but to thrive. City by city, the narrative is changing as these women carve...

Continue Reading
Stocks Jump Ahead of Critical Inflation Reports

Updated Category News Views 41

Stocks Lift as Wall Street Awaits Inflation Data Every trader's favorite game—speculation—returns as major U.S. stock benchmarks kick off Monday with some gusto. The S&P 500, Nasdaq Composite, Dow Jones Industrial Average, and Russell 2000 all saw gains in the early morning session, signaling positive vibes across the board. Numbers don't lie, folks: The S&P climbed...

Continue Reading
Korean 'Glocal' Districts Entice U.S. Tourists with Local Flavor

Updated Category News Views 164

Gwangju's Dongmyeong-dong is like the neighborhood artists and hipsters flock to in New York—except it’s got a Korean twist. Nestled in the Jeonnam region, this place is hot on American tourists' radar for its spicy mix of local culture, unique eats, and shops that scream individuality. It's becoming a magnet for folks who want to get a taste of Korean life but with a...

Continue Reading
Vinamilk's Optimum Gold Shines at Global Awards

Updated Category News Views 49

A Win Beyond Borders: Vinamilk's Global Recognition Sometimes, you gotta hand it to the underdog who comes out swinging and bags the big trophy. This time, it's Vinamilk's Optimum Gold nabbing the "Brand of the Year" at the World Branding Awards 2026-2027. Kicking open international doors from a quaint start in Vietnam to now shining under London's glittery skyline,...

Continue Reading

Top 5 Most Recently Viewed Articles

TGS ASA Engages Fixed Income Investors for Key Meetings

Updated Category News Views 137

TGS ASA Engages in Important Fixed Income Investor Meetings Oslo, Norway – TGS ASA, a pioneering force in energy data and intelligence, is preparing to engage with fixed income investors over a series of meetings. Scheduled to commence on a Monday, these meetings will see participation from notable institutions including J.P. Morgan, Danske Bank, and DNB Markets,...

Continue Reading
Man Group PLC's Disclosure on Urban Logistics REIT plc Holdings

Updated Category News Views 135

Understanding Man Group PLC's Recent Disclosure In the world of finance, transparency is key. This recent announcement from Man Group PLC serves as a public opening position disclosure concerning Urban Logistics REIT plc. It highlights the interests and positions held by a person in the relevant securities that are 1% or greater, adhering to Rule 8.3 of the Takeover Code....

Continue Reading
Understanding the Shift in Employer Attitudes Towards Talent

Updated Category News Views 221

Understanding the Shift in Employer Attitudes Towards Talent A recent survey unveiled significant insights into hiring practices and employer attitudes regarding overqualified candidates. Employers often welcome these candidates, yet they harbor deep concerns about retention and engagement, which leaves many job seekers feeling anxious. This changing perspective...

Continue Reading
GeneDx Reports Q4 Earnings: Analysts React with Price Cuts

Updated Category News Views 218

Unpacking the Earnings Surprise Can’t say I didn’t see that one coming. GeneDx (NASDAQ:WGS) drops some profits like it’s hot for Q4, clocking in earnings of 14 cents per share. That’s a solid beat compared to the 11-cent consensus the suits on Wall Street were whispering about. You can’t shake a stick at that, right? Well, not so fast—because the stock took a...

Continue Reading
Investing in Freeport-McMoRan: A 10-Year Perspective

Updated Category News Views 197

A Deep Dive into Freeport-McMoRan's Journey Alright, let’s cut to the chase. Freeport-McMoRan (NYSE: FCX)—this name's been buzzing on the trading floor for a while now. If you had put down $100 in FCX stock a decade ago, buckle up—your investment would be sitting pretty at about $859.11 today. That’s quite the leap, huh? In a market that shifts gears faster than a...

Continue Reading